U.S. President Donald Trump¡¯s push for lower U.S. drug prices has unexpectedly helped Astellas Pharma secure higher reimbursement pricing for its new eye medicine in Japan.
The Tokyo-based drugmaker, in a submission to Japanese officials, argued that domestic drug costs could influence U.S. pricing under Trump¡¯s proposed most-favored nation scheme. Following this, Astellas won a reimbursement level for Izervay that was more generous than typical outcomes, Chief Executive Officer Naoki Okamura said in an interview.
¡°We leveraged this most favored nation dialog,¡± Okamura said. He believes Izervay got ¡°relatively reasonable pricing¡± in Japan.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.